A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
Christian LewinterTorsten Holm NielsenLars Robert EdforsCecilia LindeJohn Martin BlandM LeWinterJohn G F ClelandLars Valeur KøberFrieder BraunschweigAgneta Mansson-BrobergPublished in: European heart journal (2022)
Both BB and ACEI/ARB therapies were associated with the preservation of LVEF during trastuzumab and anthracycline-containing regimens as compared with placebo, suggesting both to be beneficial.
Keyphrases
- epidermal growth factor receptor
- left ventricular
- metastatic breast cancer
- heart failure
- growth factor
- oxidative stress
- acute myocardial infarction
- tyrosine kinase
- angiotensin converting enzyme
- hypertrophic cardiomyopathy
- cardiac resynchronization therapy
- aortic stenosis
- mitral valve
- double blind
- phase iii
- randomized controlled trial
- recombinant human
- atrial fibrillation
- coronary artery disease
- transcatheter aortic valve replacement